Cargando…

Implementation of ML searches in CheckMATE

I will discuss a recent CheckMATE implementation of ATLAS searches using MVA/BDT and NN methods.

Detalles Bibliográficos
Autor principal:	Rolbiecki, Krzysztof
Lenguaje:	eng
Publicado:	2022
Materias:	Workshops
Acceso en línea:	http://cds.cern.ch/record/2845169

Ejemplares similares

Implementation of multi-bin searches in CheckMATE
por: Lara Perez, Iñaki
Publicado: (2022)

CheckMATE tutorial
por: Kim, Jong Soo, et al.
Publicado: (2021)

Recent developments in CheckMATE 2
por: Wang, Zeren Simon
Publicado: (2021)

EWino searches in CheckMate and $(g-2)_\mu$ in the MSSM
por: Chakraborti, Manimala
Publicado: (2021)

From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
por: Deng, Haiyi, et al.
Publicado: (2021)

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
por: Ready, Neal, et al.
Publicado: (2018)

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
por: Filley, Anna C., et al.
Publicado: (2017)

CheckMate 214 trial: Immune checkpoint regulators for advanced renal cell carcinoma
por: Jena, Rahul
Publicado: (2020)

Different interpretations of the CheckMate-227 trial in non-small-cell lung cancer
por: Su, Zheng
Publicado: (2020)

Health-related quality of life results from the phase III CheckMate 067 study
por: Schadendorf, Dirk, et al.
Publicado: (2017)

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
por: Lee, Alexandria T M, et al.
Publicado: (2023)

A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577
por: Pape, Marieke, et al.
Publicado: (2022)

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
por: O’Byrne, K.J., et al.
Publicado: (2022)

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
por: Owonikoko, Taofeek K., et al.
Publicado: (2021)

CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?
por: Su, David, et al.
Publicado: (2023)

CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

Check(point) or checkmate for acute myeloid leukemia?
por: Niyongere, Sandrine, et al.
Publicado: (2021)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

ESMO20 YO for YO: highlights on metastatic renal cell carcinoma—the CheckMate-9ER trial
por: Kfoury, M., et al.
Publicado: (2021)

Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial
por: Lin, Yan, et al.
Publicado: (2023)

ALICE: ML and DA Challenges
por: Floris, Michele
Publicado: (2016)

CMS: ML and DA Challenges
por: Vlimant, Jean-Roch
Publicado: (2016)

ATLAS: ML and DA Challenges
por: Rousseau, David
Publicado: (2016)

LHCb: ML and DA Challenges
por: Ustyuzhanin, Andrey
Publicado: (2016)

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
por: Tomita, Yoshihiko, et al.
Publicado: (2017)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
por: Reardon, David A., et al.
Publicado: (2020)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
por: Emamekhoo, Hamid, et al.
Publicado: (2021)

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)
por: Sangro, Bruno, et al.
Publicado: (2023)

CMS inputs on ML models re-usability
por: Ngadiuba, Jennifer
Publicado: (2022)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study
por: Julien, Karen, et al.
Publicado: (2020)

Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial
por: Sato, Yasuyoshi, et al.
Publicado: (2020)

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
por: Yau, Thomas, et al.
Publicado: (2023)

Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics—CheckMate 908
por: Dunkel, Ira J, et al.
Publicado: (2023)

GraphML-SBGN bidirectional converter for metabolic networks
por: Balaur, Irina, et al.
Publicado: (2022)

Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
por: Omuro, Antonio, et al.
Publicado: (2022)

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141
por: Gillison, Maura L, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h4tfa1htkjddo54r01tnn6t468